This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Report Card: Steven Tighe

Steven Tighe
Merrill Lynch
Report Card
1*
Overall rank
1* Rank by institutions
19* Rank by stock picking
Makes money for me
Saves me from disaster
Makes me think
Tells the truth
Meaningful service, not overkill
Well-connected
*Out of 28.
Best star rating is 3 stars. Click here for our methodology.
1st Place
Pharmaceuticals




Bio

B.S., M.S., University of California, San Diego; M.B.A., Wharton School, University of Pennsylvania. Tighe has been covering pharmaceutical companies at Merrill Lynch since 1996. He heads the firm's global pharmaceuticals research. Tighe also spent 10 years at J.P. Morgan, first in research as a pharmaceuticals and biotechnology analyst and later in corporate finance engaged primarily in advisory and mergers and acquisitions work. He is vice chairman of the board of trustees, National Foundation for Infectious Diseases.

Industry Outlook and Style

The Winners
By name
By category
By firm
Best stock pickers
Best firms
The pluses in the pharmaceutical industry will outweigh the possible minuses over the next 12 months, predicts Tighe. He believes that the group will deliver faster earnings growth than the rest of the market in the second half of 2000 and into next year.

Tighe likes the earnings-growth prospects for two companies in particular -- Pfizer (PFE) and Pharmacia (PHA). Both completed major mergers earlier this year: Pfizer bought Warner Lambert (Merrill Lynch advised Pfizer on that hostile offer) and Pharmacia acquired Monsanto. According to Tighe, both have fabulous product portfolios with strong trends that will accelerate earnings by 25% or so. He believes that the group will deliver superior earnings acceleration relative to the broader market in the second half of 2000 and into next year.

"Just look at Pfizer's product line," Tighe says. With the Warner Lambert stable came Lipitor, which lowers cholesterol, and Neurontin for epilepsy and pain. Pfizer's product portfolio already consisted of Zithromax (an antibiotic), Zyrtec (for allergies), Norvasc (for hypertension or high blood pressure), Zoloft (for depression) and Viagra (for erectile dysfunction). Moreover, Pfizer is copromoting Pharmacia's Celebrex, a Cox-2 inhibitor for osteoarthritic and rheumatoid arthritis.

Tighe continues to do "original work when so many other sell-siders only parrot" management, says a client who voted in TheStreet.com's Analyst Rankings -- Equity 2000. Indeed, before his shop was named adviser to Pfizer, Tighe published a comment explaining why a possible Pfizer-Warner Lambert merger would be "a great transaction."

Tighe considers Pharmacia his second-favorite name after Pfizer. He points out that the company continues to develop its prosperous Cox-2 inhibitor franchise, which includes Celebrex, launched in 1998. It is introducing a new class of drugs on the antibiotic front. And it remains a leader in oncology products.

Tighe's third pick among large-cap pharmas is Eli Lilly (LLY), which "has a really interesting pipeline of products that holds the possibility of earnings-growth acceleration in coming years," he says.

The one big risk, says Tighe, is politics. Washington holds the cards on the Medicare prescription drug-benefit plan. If enacted, the plan could put pressure on drug pricing. While he believes that the November elections will stall movement on the Medicare front this year, Tighe frets about other possible legislation, such as an attempt to repeal importation bans on foreign-made drugs.

Tighe's recent newsmaking calls have focused on the smaller drug companies. He lowered his rating on Forest Labs (FRX) from a buy to an intermediate-term accumulate, and raised his rating on Alza (AZA) in anticipation of the summer launch of Johnson & Johnson's Concert, an attention-deficit hyperactivity disorder drug that Alza is copromoting. (Merrill Lynch has a longtime investment banking relationship with Alza.)

Stock Pick

Favorite stock for next 12 months:
Pfizer

Comment:
With its second-quarter acquisition of Warner Lambert, Pfizer has further diversified and enhanced its product portfolio while reducing costs, Tighe says. The combined entity now has "multiple phenomenal franchises supported by a U.S. sales force 60% larger than that of its nearest competitor." Tighe expects Pfizer's earnings growth to surpass the industry and the market. The stock is now 45; Tighe's intermediate-term price target is 60.


Rate Their Stock Picks:

Which stock do you like best? Tighe and Scala: Pfizer Rubin: Schering-Plough


As originally published, this story contained an error. Please see Corrections and Clarifications.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs